DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa

Information source: Otic Pharma
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Otitis Externa; Otorhinolaryngologic Diseases; Ear Diseases; Otitis

Intervention: 0.3% Ciprofloxacin Ear Drops (Drug); 0.3% Ciprofloxacin Foam Otic Cipro (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Otic Pharma

Official(s) and/or principal investigator(s):
Yehudah Roth, MD, Principal Investigator, Affiliation: Edith Wolfson Medical Center


The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro, a novel medication developed to treat Acute Diffuse Otitis Externa of bacterial origin. The working hypothesis is that Foam Otic Cipro is as effective as registered ear drops.

Clinical Details

Official title: Bioequivalence of Ciprofloxacin 0.3%: a Randomized, Multicenter, Parallel, Comparative Study on the Safety and Efficacy of Ciprofloxacin 0.3% in a Standard Solution or Foam Solution, in Patients With Acute External Otitis.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Clinical cure confirmed by significant reduction or absence of the disease symptoms a) Otalgia, b) tenderness with movement of pinna, and c) edema/ear canal occlusion

Detailed description: Acute otitis externa (AOE) is defined as a diffuse inflammation of the external ear canal, which may also involve the pinna and/or the tympanic membrane. AOE is one of the most common infections encountered by otolaryngologists, pediatricians and family physicians. The reported annual incidence of AOE is between 1: 100 and 1: 250 in the general population with large seasonal and regional variations. Diagnosis of AOE requires rapid onset (generally within 48 hours) of symptoms and signs of ear canal inflammation which includes: A) otalgia (often severe), itching or fullness, sometimes accompanied by reduced hearing or jaw pain; B) tenderness of the tragus and/or pinna; and C) diffuse ear canal edema with or without erythema, sometimes accompanied by ear discharge.


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- Aged 18 and older eligible to sign by themselves.

- Have a clinical diagnosis of Acute Otitis Externa based on clinical observation and

of presumed bacterial origin.

- Intact tympanic membrane

- Unilateral Acute Otitis Externa

Exclusion Criteria:

- Known allergy or sensitivity to Ciprofloxacin or other quinolones.

- Clinical Diagnosis of chronic suppurative otitis media (CSOM), acute otitis media

(AOM), involvement of middle ear effusion (MEE).

- Patient has the non intact tympanic membrane.

- Patient has a serious underlying disease.

- Patients with known history of immune dysfunction/deficiency and those receiving

immunosuppressive therapy.

- Patients with history of Diabetes mellitus.

- Bilateral Acute Otitis Externa.

- Patients with more than 80% of the ear canal occluded.

- Pregnant or lactating patients.

- Overt fungal Acute Otitis Externa.

- Local ear canal abnormalities such as abscess, granulation or polyps.

- Congenital abnormalities of the external auditory canal or obstructive bony exostosis

in the treated ear.

- Mastoid or other suppurative non-infectious ear disorder (e. g. cholesteatoma) in the

treated ear.

- Seborrheic dermatitis or other dermatological conditions of the external auditory

canal which would complicate evaluation.

- Current Infection requiring systemic antimicrobial therapy.

- Current or previous use of topical or oral antibiotics (within 3 days) or long-acting

antibiotics (within 7 days).

- Current enrollment in an investigational drug or device study or participation in

such a study within 30 days of entry into this study.

Locations and Contacts

HaEmek Medical Center, Afula, Israel

Wolfson Medical Center, Holon 58100, Israel

Maccabi Healthcare Services, Tel Aviv 68125, Israel

Assaf Harofeh Medical Center, Zerifin 70300, Israel

Additional Information

Starting date: May 2009
Last updated: December 23, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017